Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Cona
Clinical trial register · Italy

Clinical Trials in Cona, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC
6778
Studies in scope
all four open statuses
4069
Recruiting now
open to new participants
1018
Lead sponsors
across recruiting studies
Top sites
Milan 2843 Bologna 1305 Roma 1274 Naples 984 Rome 967
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Novartis Pharmaceuticals14 AstraZeneca12 Sanofi7 AbbVie5 Eli Lilly and Company3
Site location
Milan2843 Bologna1305 Roma1274 Naples984 Rome967
All 489 locations
Target enrolment
to

Trials with a site in Cona

78 of 6778 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Recruiting
Takeda
Phase 3
324
Bologna, Cona, Meldola, Rome, Milan, Ancona, Catania, Florence
2026-09-10
Recruiting
AstraZeneca
Phase 3
1,072
Brescia, Cona, Florence, Milan, Roma
2026-08-31
Recruiting
Novartis Pharmaceuticals
Phase 3
5,700
Ancona, Bergamo, Bologna, Brescia, Cona, Florence, Pozzilli, Milan
2026-05-11
Not yet open
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2
108
Bologna, Cuneo, Meldola, Cona, Lido di Camaiore, Lucca, Mantua, Pisa
2026-05
Recruiting
Novartis Pharmaceuticals
Phase 2
210
Ancona, Cona, Milan, Rozzano
2026-03-09
Recruiting
GlaxoSmithKline
Phase 1
44
Cona
2026-02-10
Recruiting
AstraZeneca
Observational
218
Monserrato, Cona, San Giovanni Rotondo, Rozzano, Ancona, Bari, Brescia, Florence
2025-12-31
Recruiting
Sanofi
Phase 2
144
Torette, Cona, Garbagnate Milanese, Milan, Brescia, Chieti, Pisa
2025-12-29
Recruiting
Novartis Pharmaceuticals
Observational
250
Ancona, Bari, Brescia, Cona, Florence, Genova, Lecce, Messina
2025-12-17
Recruiting
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
NCT07226986PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
DrugsAbiraterone·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
123
Cona, Milan, Naples
2025-12-05
Recruiting
AbbVie
Phase 3
561
Cona, Florence, Rome, Ancona, Reggio Emilia
2025-11-05
Recruiting
Acesion Pharma
Phase 2
200
Bologna, Cona, Mestre, Milan, Modena
2025-10-22
Recruiting
Novo Nordisk A/S
Phase 3
1,280
Ancona - Torrette, Bologna, Bolzano, Brescia, Cona, Florence, Ivrea, Lecco
2025-10-02
Recruiting
Sanofi
Phase 4
218
Cona, Giugliano in Campania, Orbassano, Siena
2025-09-22
Recruiting
AbbVie
Observational
2,795
Cona, Rome, Bari
2025-09-02
Recruiting
Relay Therapeutics, Inc.
Phase 3
540
Ancona, Brescia, Candiolo, Cona, Florence, Livorno, Meldola, Milan
2025-08-26
Recruiting
Novartis Pharmaceuticals
Observational
300
Alessandria, Asti, Bergamo, Brescia, Catania, Meldola, Cona, Foggia
2025-07-30
Recruiting
Left Bundle Branch Area Pacing (LBBAP) PMCF Study
NCT07217392Bradycardia, Right Ventricular Pacing, Heart Failure, Atrial Fibrillation (AF)
Abbott Medical Devices
Not applicable
200
Cona
2025-07-24
By invitation
MoonLake Immunotherapeutics AG
Phase 3
835
Catania, Chieti, Cona, Florence, Milan, Modena, Naples, Perugia
2025-06-27
Active, closed
Incyte Corporation
Phase 3
580
Catania, Cona, Florence, Milan, Naples, Roma, Rozzano, Torino
2025-06-23
Recruiting
AstraZeneca
Phase 3
15,100
Altamura, Arzignano, Bergamo, Bologna, Brescia, Caserta, Catania, Cona
2025-06-04
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
Cona, Genova, Milan, Rozzano, Pisa, Roma
2025-05-30
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Ancona, Cona, Pisa
2025-05-16
Recruiting
AstraZeneca
Phase 3
990
Cona, Florence, Milan, Montebelluna, Naples, Pavia, Roma, Sassari
2025-03-18
Recruiting
AstraZeneca
Phase 3
11,300
Alessandria, Bari, Bergamo, Brescia, Chiavari, Cona, Foggia, Milan
2025-03-14
Active, closed
Sanofi
Phase 3
231
Cona, Florence, Genoa, Milan, Padua, Rome, Bologna
2025-02-12
Active, closed
Novartis Pharmaceuticals
Phase 3
588
Ancona, Brescia, Catania, Cona, Florence, Rozzano, Modena, Pisa
2025-01-31
Recruiting
BioNTech SE
Phase 2/3
1,580
Avellino, Aviano, Bologna, Candiolo, Catania, Cona, Cremona, Lucca
2025-01-07
Recruiting
Loxo Oncology, Inc.
Phase 2
249
Bari, Cona, Florence, Milan, Novara, Padova, Palermo, Perugia
2025-01-03
Recruiting
Cytokinetics
Phase 3
1,800
Brescia, Rimini, Arzignano, Bergamo, Milan, Sesto San Giovanni, Perugia, Cona
2024-12-19
Active, closed
Sanofi
Phase 2
556
Torette, Monserrato, Cona, Genoa, Milan, Rozzano, Rome, Bergamo
2024-11-07
Active, closed
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
NCT06430866Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
DrugsABP 234·Pembrolizumab
Amgen
Phase 3
163
Cona, Cuneo, Florence, Lucca, Monserrato, Naples, Peschiera del Garda, Ravenna
2024-09-12
Active, closed
Amgen
Phase 3
315
Cona, Cremona, Milan, Naples, Ravenna, Sondrio, Terni
2024-09-09
Recruiting
San Luigi Gonzaga Hospital
Not applicable
360
Aosta, Biella, Cuneo, Cona, Genova, Rivoli, Trapani, Orbassano
2024-09-01
Active, closed
Novartis Pharmaceuticals
Observational
379
Ancona, L’Aquila, Bari, Bergamo, Chieti, Catania, Catanzaro, Cona
2024-07-30
Active, closed
AstraZeneca
Phase 3
339
Brescia, Cona, Florence, Milan, Naples, Reggio Emilia, Roma, Rome
2024-06-29
Active, closed
AbbVie
Phase 3
1,400
Cona, Florence, Rozzano, Naples, Rome, Catania, Milan
2024-06-27
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Cona, Pisa, Roma, Torino
2024-05-21
Recruiting
AstraZeneca
Phase 3
3,850
Acquaviva delle Fonti, Bari, Bergamo, Brescia, Catania, Catanzaro, Cona, Cortona
2024-04-12
Recruiting
International Extranodal Lymphoma Study Group (IELSG)
Observational
300
Alessandria, Bari, Bergamo, Brescia, Catania, Cona, Florence, Messina
2024-04-11
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Brescia, Cona, Genova, Milan, Rozzano, Pisa, Roma, Negrar
2024-03-12
Recruiting
Novartis Pharmaceuticals
Phase 2
502
Ancona, Bergamo, Bologna, Brescia, Caserta, Cona, Pozzilli, Milan
2024-03-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Cona, Meldola, Milan, Florence, Pisa, Castelfranco Veneto, Alessandria, Ancona
2023-12-31
Active, closed
Sanofi
Phase 3
943
Augusta, Cona, Florence, Genoa, Milan, Naples, Cefalù, Rome
2023-12-27
Recruiting
Ascentage Pharma Group Inc.
Phase 3
400
Aviano, Brescia, Cona, Genova, Lecce, Meldola, Milan, Padova
2023-12-20
Active, closed
Sanofi
Phase 3
1,655
Cona, Florence, Genoa, Milan, Monza, Naples, Rome, Orbassano
2023-12-13
Recruiting
Intellia Therapeutics
Phase 3
1,200
Bologna, Cona, Florence, Genova, Pavia, Pisa, Trieste
2023-12-13
Active, closed
AstraZeneca
Phase 3
314
Ancona, Brescia, Cona, Milan, Padova, Roma
2023-11-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
14,550
Cona, Rome, Bergamo, Brescia, Milan, Monza, Turin, Palermo
2023-10-09
Active, closed
AbbVie
Phase 3
1,328
Cona, Florence, L’Aquila, Rome, Brescia, Milan, Modena, Pisa
2023-06-21
Recruiting
Platform of Randomized Adaptive Clinical Trials in Critical Illness
NCT05440851Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High
University Health Network, Toronto
Not applicable
6,250
Cona, Foggia, Milan, Legnano, Palermo, Roma, Sassari, Trento
2023-04-30
Active, closed
Novartis Pharmaceuticals
Phase 3
288
Ancona, Cona, Padova, Pisa, Roma, Torino
2023-04-21
Active, closed
Pfizer
Phase 3
624
Naples, Misterbianco, Bologna, Cona, Rome, Monza, Ancona, Pisa
2023-03-03
Active, closed
AstraZeneca
Observational
551
Naples, Cona, Udine, Rome, Brescia, Milan, Turin, Cagliari
2023-02-27
Recruiting
University Hospital of Ferrara
Observational
500
Cona
2022-09-09
Active, closed
Precise Procedural and PCI Plan (P4)
NCT05253677Coronary Artery Disease
CoreAalst BV
Not applicable
1,090
Cona, Milan
2022-04-01
Active, closed
AstraZeneca
Phase 3
363
Ancona, Cona, Eboli, Padova, Roma
2022-02-15
Recruiting
Sanofi
Phase 3
284
Cona, Florence, Milan, Rozzano, Naples, Rome, Ancona
2022-02-15
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
DrugsEylea·Aflibercept
AbbVie
Phase 3
735
Cona, Milan, Naples, Rome, Negrar, Bari, Chieti, Udine
2022-01-13
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Bologna, Brescia, Cona, Florence, Grosseto, Pozzilli, Milan, Rozzano
2021-11-23
Active, closed
Loxo Oncology, Inc.
Phase 3
600
Bologna, Catanzaro, Cona, Cuneo, Florence, Meldola, Milan, Modena
2021-09-20
By invitation
Viatris Innovation GmbH
Phase 3
25,000
Arezzo, Bologna, Caserta, Catania, Catanzaro, Cona, Florence, Messina
2021-08-14
Active, closed
Geron Corporation
Phase 3
327
Alessandria, Bologna, Cona, Florence, Genova, Milan, Ravenna, Reggio Calabria
2021-04-12
Active, closed
AstraZeneca
Phase 3
866
Aviano, Bergamo, Candiolo, Cona, Genova, Livorno, Messina, Milan
2020-07-24
Active, closed
Gruppo Italiano Malattie EMatologiche dell'Adulto
Observational
321
Cona, Alessandria, Bari, Cagliari, Catania, Catanzaro, Cosenza, Florence
2020-07-24
Recruiting
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
NCT04071847Movement Disorders, Parkinson Disease, Essential Tremor, Tremor
Abbott Medical Devices
Observational
1,000
Cona, Rome, Milan
2019-11-26
Recruiting
University Hospital Muenster
Phase 3
683
Ancona, Bari, Bergamo, Bologna, Brescia, Cagliari, Catania, Cona
2019-08-23
Active, closed
AstraZeneca
Phase 2
273
Ancona, Bologna, Brescia, Cona, Genova, Lecco, Meldola, Messina
2018-03-07
Recruiting
Scaffold in Emilia Romagna and in the MAGIC Network
NCT03327961Coronary Artery Disease
University Hospital of Ferrara
Observational
1,111
Agrigento, Treviglio, Bologna, Savigliano, Cona, Forlì, Modena, Parma
2017-12-02
Active, closed
Gruppo Italiano Malattie EMatologiche dell'Adulto
Observational
530
Ancona, Bologna, Brindisi, Cagliari, Catania, Catanzaro, Cona, Cosenza
2017-11-13
Active, closed
Eli Lilly and Company
Phase 3
5,637
Naples, Cona, Meldola, Monza, Milan, Rozzano, Rome, Terni
2017-07-12
Active, closed
Alliance Foundation Trials, LLC.
Phase 3
518
Bologna, Cona, Milan, Segrate, Udine
2017-06-21
Active, closed
Acerta Pharma BV
Phase 3
533
Bologna, Cagliari, Cona, Florence, Meldola, Milan, Modena, Ravenna
2015-07-28
Active, closed
Eli Lilly and Company
Phase 3
493
Brindisi, Cona, Genoa, Candiolo, Prato, Negrar, Bergamo, Bologna
2014-11-06
Active, closed
Eli Lilly and Company
Phase 3
669
Cona, Rome, Bologna, Padova
2014-07-22
Recruiting
University Hospital of Ferrara
Observational
10,000
Cona
2014-06
Recruiting
PREgnancy and FERtility Registry
NCT02895165Breast Neoplasms, Pregnancy, Fertility Preservation
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Observational
1,000
Asti, Brindisi, Monserrato, Cuneo, Cona, Genoa, Lecce, Lido di Camaiore
2012-11
Recruiting
Pompe Disease Registry Protocol
NCT00231400Glycogen Storage Disease Type II, Pompe Disease
Genzyme, a Sanofi Company
Observational
2,000
Gussago, Cona, Florence, Milan, Padua, Rome, Brescia, Cagliari
2004-09-15
Rows per page Showing 1–78 of 78
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-italy/city/cona

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 78 of those studies with a site in Cona.

How many clinical trials are recruiting in Cona?

42 of the 78 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 1 have not yet opened recruitment, 33 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Cona), 78 studies
PhaseStudiesRecruitingShare
Phase 3461859%
Observational151119.2%
Phase 29611.5%
Not applicable435.1%
Phase 1111.3%
Phase 1/2111.3%
Phase 2/3111.3%
Phase 4111.3%

Most active sponsors

Lead sponsors with the most studies (Cona)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals1410
AstraZeneca126
Sanofi73
AbbVie52
Eli Lilly and Company30
University Hospital of Ferrara33
Abbott Medical Devices22
Amgen20
Gruppo Italiano Malattie EMatologiche dell'Adulto20
Loxo Oncology, Inc.21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.